Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 77.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,885 shares of the biopharmaceutical company’s stock after selling 19,650 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $4,542,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 31.4% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,363 shares of the biopharmaceutical company’s stock worth $1,052,000 after buying an additional 326 shares in the last quarter. LSV Asset Management grew its position in shares of Regeneron Pharmaceuticals by 199.5% during the 4th quarter. LSV Asset Management now owns 166,514 shares of the biopharmaceutical company’s stock valued at $128,527,000 after buying an additional 110,914 shares during the last quarter. Evoke Wealth LLC grew its position in shares of Regeneron Pharmaceuticals by 35.2% during the 4th quarter. Evoke Wealth LLC now owns 810 shares of the biopharmaceutical company’s stock valued at $625,000 after buying an additional 211 shares during the last quarter. Keudell Morrison Wealth Management bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $459,000. Finally, Global Retirement Partners LLC grew its position in Regeneron Pharmaceuticals by 132.8% in the 4th quarter. Global Retirement Partners LLC now owns 1,499 shares of the biopharmaceutical company’s stock worth $1,157,000 after purchasing an additional 855 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $638.88 on Tuesday. The company’s fifty day moving average is $729.30 and its 200-day moving average is $745.72. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The firm has a market cap of $67.54 billion, a price-to-earnings ratio of 15.57, a price-to-earnings-growth ratio of 1.41 and a beta of 0.30. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same quarter in the prior year, the business posted $8.22 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 19.0% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be paid a $0.94 dividend. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.16%.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director directly owned 17,503 shares in the company, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. BMO Capital Markets decreased their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Morgan Stanley increased their target price on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Zacks Research lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Barclays cut their price target on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Finally, Piper Sandler cut their price target on shares of Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating on the stock in a report on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $792.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.